Screening for Ovarian Cancer can Cut Down Death Rate

Screening for Ovarian Cancer can Cut Down Death Rate

Authored by DesiMD Doctor on 19 Dec 2015 - 15:41


Ovarian cancer is one of the most fatal gynaecological cancers because it remains silent for a long time and normally detected in advanced stageWith just 40% surviing for 5 years, early diagnosis helps bring better treatment outcomes, according to the study. However, according to researchers at the University College of London regular screening for ovarian cancer can reduce mortality rates by 20%. (Study are published in The Lancet Journal). Early detection of ovarian cancer have better chances of survival.

The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is one of the largest ever randomized trials. Prof. Ian Jacobs and group at the University College of London enrolled about 202640 women aged 50-74 years and allocated them randomly into three groups: 101,299 were not screened, 50,623 had an annual ultrasound scan and 50,624 underwent annual screening that involved a blood test and an ultrasound scan.

Study Findings: After a follow-up of about 11 years, ovarian cancers were determined in 630 women who had no screening, 314 women who were screened by ultrasound only, and 338 women who underwent both blood tests and ultrasound. As compared with the group that had no screening, from 0-14 years, study showed:

  • Mortality rate was reduced among those screened by blood test and ultrasound by 15%
  • And those screened only by ultrasound showed 11% reduction in mortality rate.

Prof. Jacobs says, "These results from UKCTOCS provide estimates of the mortality reduction attributable to ovarian cancer screening which range from 15% to 28%. Further follow-up in UKCTOCS will provide greater confidence about the precise reduction in mortality which is achievable. It is possible that the mortality reduction after follow-up for an additional 2-3 years will be greater or less than these initial estimates."


Reference:Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial, Ian J Jacobs et al., The Lancet, doi:, published online 17 December 2015.



*Disclaimer: This website serves as informational purpose only. The content on the DesiMD website, including text, graphics, images, etc., and other content on the DesiMD are for informational purpose only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on the DesiMD website. In case of a medical emergency, call your physician or the hospital immediately. DesiMD does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on the site. Reliance on any information provided by DesiMD at the invitation of DesiMD, or other visitors to the site is solely at your own risk.